Company Data

AIM ImmunoTech Inc.

Ticker
AIM
Current Price
$0.4006 -0.1%
Market Cap
$19.6M
Price Target
Refer to Report
Volume
70.1K
52wk Range
$0.379 - $0.7487
Advanced Market Data

Overview

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM’s flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Inbox Intel from Channelchek.

Informed investors make more money. And itโ€™s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
ยฉ 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.